Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Dec 23

PMID 36556483

Authors

Rebeca Perez

Talita Glaser

Cecilia Villegas

Viviana Burgos

Henning Ulrich

Cristian Paz

Affiliations

Soon will be listed here.

Abstract

is one of the first medicinal plants used by humans. Its medical use remains controversial because it is a psychotropic drug whose use has been banned. Recently, however, some countries have approved its use, including for recreational and medical purposes, and have allowed the scientific study of its compounds. is characterized by the production of special types of natural products called phytocannabinoids that are synthesized exclusively by this genus. Phytocannabinoids and endocannabinoids are chemically different, but both pharmacologically modulate CB1, CB2, GRP55, GRP119 and TRPV1 receptor activities, involving activities such as memory, sleep, mood, appetite and motor regulation, pain sensation, neuroinflammation, neurogenesis and apoptosis. Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are phytocannabinoids with greater pharmacological potential, including anti-inflammatory, neuroprotective and anticonvulsant activities. Cannabidiol is showing promising results for the treatment of COVID-19, due to its capability of acting on the unleashed cytokine storm, on the proteins necessary for both virus entry and replication and on the neurological consequences of patients who have been infected by the virus. Here, we summarize the latest knowledge regarding the advantages of using cannabinoids in the treatment of COVID-19.

Citing Articles

Cannabis: Zone Aspects of Raw Plant Components in Sport-A Narrative Review.

Flangea C, Vlad D, Popescu R, Dumitrascu V, Rata A, Tryfon M Nutrients. 2025; 17(5).

PMID: 40077729 PMC: 11902196. DOI: 10.3390/nu17050861.

Dried Cannabis Use, Tobacco Smoking, and COVID-19 Infection: Findings from a Longitudinal Observational Cohort Study.

Milad N, Belisario K, MacKillop J, Hirota J Cannabis. 2025; 7(3):177-192.

PMID: 39781558 PMC: 11705037. DOI: 10.26828/cannabis/2024/000248.

Cannabis sativa L.: A comprehensive review on legislation, decriminalization, phytochemistry, antimicrobial activity, and safety.

Dalli M, Azizi S, Azghar A, Saddari A, Benaissa E, Ben Lahlou Y J Food Drug Anal. 2024; 31(3):408-435.

PMID: 39666278 PMC: 10629910. DOI: 10.38212/2224-6614.3471.

Secondary metabolite profiles and anti-SARS-CoV-2 activity of ethanolic extracts from nine genotypes of Cannabis sativa L.

Schadich E, Kaczorova D, Beres T, Dzubak P, Hajduch M, Tarkowski P Arch Pharm (Weinheim). 2024; 358(1):e2400607.

PMID: 39543317 PMC: 11726160. DOI: 10.1002/ardp.202400607.

Immunomodulatory effects of cannabinoids against viral infections: a review of its potential use in SARS-CoV2 infection.

Hassan Kalantar Neyestanaki M, Gholizadeh O, Hosseini Tabatabaie F, Akbarzadeh S, Yasamineh S, Afkhami H Virusdisease. 2024; 35(2):342-356.

PMID: 39071880 PMC: 11269557. DOI: 10.1007/s13337-024-00871-0.

References

Henstridge C, Balenga N, Schroder R, Kargl J, Platzer W, Martini L . GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol. 2010; 160(3):604-14. PMC: 2931561. DOI: 10.1111/j.1476-5381.2009.00625.x. View

Crippa J, Derenusson G, Ferrari T, Wichert-Ana L, Duran F, Martin-Santos R . Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2010; 25(1):121-30. DOI: 10.1177/0269881110379283. View

Park M . Macrophages: a Trojan horse in COVID-19?. Nat Rev Immunol. 2020; 20(6):351. PMC: 7186930. DOI: 10.1038/s41577-020-0317-2. View

Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong M, Valmaggia L . Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl). 2020; 237(4):1121-1130. PMC: 7113209. DOI: 10.1007/s00213-019-05442-6. View

Sarafian T, Montes C, Harui A, Beedanagari S, Kiertscher S, Stripecke R . Clarifying CB2 receptor-dependent and independent effects of THC on human lung epithelial cells. Toxicol Appl Pharmacol. 2008; 231(3):282-90. PMC: 2615389. DOI: 10.1016/j.taap.2008.05.001. View

Wang B, Kovalchuk A, Li D, Rodriguez-Juarez R, Ilnytskyy Y, Kovalchuk I . In search of preventive strategies: novel high-CBD extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY). 2020; 12(22):22425-22444. PMC: 7746344. DOI: 10.18632/aging.202225. View

Neumeister A, Normandin M, Pietrzak R, Piomelli D, Zheng M, Gujarro-Anton A . Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013; 18(9):1034-40. PMC: 3752332. DOI: 10.1038/mp.2013.61. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Szaflarski J, Bebin E, Cutter G, DeWolfe J, Dure L, Gaston T . Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018; 87:131-136. DOI: 10.1016/j.yebeh.2018.07.020. View

10.

Gertsch J . Editorial: Lung macrophages high on cannabinoids: jamming PAMs and taming TAMs?. J Leukoc Biol. 2016; 99(4):518-20. DOI: 10.1189/jlb.3CE0915-409RR. View

11.

Mayo L, Asratian A, Linde J, Morena M, Haataja R, Hammar V . Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biol Psychiatry. 2019; 87(6):538-547. DOI: 10.1016/j.biopsych.2019.07.034. View

12.

Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colin R . The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci. 2008; 122(6):1378-82. DOI: 10.1037/a0013278. View

13.

Gloss D . An Overview of Products and Bias in Research. Neurotherapeutics. 2015; 12(4):731-4. PMC: 4604179. DOI: 10.1007/s13311-015-0370-x. View

14.

Brown J . Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug-Drug Interactions. J Clin Med. 2020; 9(4). PMC: 7231229. DOI: 10.3390/jcm9040919. View

15.

Bergamaschi M, Queiroz R, Chagas M, de Oliveira D, De Martinis B, Kapczinski F . Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011; 36(6):1219-26. PMC: 3079847. DOI: 10.1038/npp.2011.6. View

16.

Weisberg E, Sattler M, Yang P, Parent A, Gray N, Griffin J . Current therapies under investigation for COVID-19: potential COVID-19 treatments. Can J Physiol Pharmacol. 2020; 98(8):483-489. DOI: 10.1139/cjpp-2020-0286. View

17.

Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F . Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?. Int J Mol Sci. 2020; 21(11). PMC: 7312493. DOI: 10.3390/ijms21113809. View

18.

Vuolo F, Petronilho F, Sonai B, Ritter C, Hallak J, Zuardi A . Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma. Mediators Inflamm. 2015; 2015:538670. PMC: 4458548. DOI: 10.1155/2015/538670. View

19.

Anil S, Shalev N, Vinayaka A, Nadarajan S, Namdar D, Belausov E . Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep. 2021; 11(1):1462. PMC: 7809280. DOI: 10.1038/s41598-021-81049-2. View

20.

Kaplan B, Springs A, Kaminski N . The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol. 2008; 76(6):726-37. PMC: 2748879. DOI: 10.1016/j.bcp.2008.06.022. View